Companies · Biotechnology
JUPITER · Biotechnology
Diligence memoA one-page analyst read on X-Vax Technology, Inc. — recommendation, valuation, rhythm, risks.→X-Vax Technology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
X-Vax Technology, Inc. is one of 4293 Biotechnology companies tracked from JUPITER. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 84% of sector peers (real $). Modeled value above 95% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 41.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Genesis Biopharma, Inc | Series C | $131.5M | $4.1B | 2.00× |
| Alder Biopharmaceuticals Inc | Series C | $100.0M | $4.1B | 2.00× |
| Ideaya Biosciences, Inc. | Series C | $111.4M | $3.9B | 1.88× |
| Stoke Therapeutics, Inc. | Series C | $90.8M | $3.7B | 1.80× |
| 4D Molecular Therapeutics Inc | Series C | $108.6M | $3.7B | 1.80× |
| Sutro Biopharma Inc | Series C | $85.4M | $3.5B | 1.71× |
| Evelo Biosciences, Inc. | Series C | $131.5M | $3.3B | 1.63× |
| Celularity Inc. | Series C | $117.7M | $3.2B | 1.55× |
| Codiak BioSciences, Inc. | Series C | $107.5M | $3.1B | 1.53× |
| Arcturus Therapeutics Ltd. | Series C | $67.8M | $2.8B | 1.36× |
| Celldex Therapeutics, Inc. | Series C | $64.5M | $2.6B | 1.25× |
| Micell Technologies Inc | Series C | $62.1M | $2.5B | 1.24× |
| X-Vax Technology, Inc. this company | Series C | $56.6M | $2.3B | 1.13× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $100K | 2016-09-06 | $556K | $5.5M | 85% |
| Series C | $46.7M | 2018-09-28 | $311.2M | $1.9B | 90% |
| Series C | $42.2M | 2018-09-28 | $281.2M | $1.7B | 90% |
| Series B | $39.3M | 2018-09-28 | $218.2M | $1.6B | 90% |
| Series C | $56.5M | 2018-09-28 | $376.4M | $2.3B | 90% |
| Series A | $6.5M | 2018-09-28 | $29.8M | $236.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Isaac Blech | — | 13 other | 2016-09 |
| Robert Ruffolo | — | 7 other | 2016-09 |
| Brian D. Finn | — | 3 other | 2018-09 |
| Roger J. Pomerantz | — | 3 other | 2018-09 |
| Roger Pomerantz | — | 3 other | 2016-09 |
| Ian T. Clark | — | 1 other | 2018-09 |
| Jacob Uittenbogaard | — | 1 other | 2018-09 |
| Matthew R. Stober | — | 1 other | 2018-09 |
| Roger A. Jeffs | — | 1 other | 2018-09 |
| William A Haseltine | — | 1 other | 2016-09 |
| Andreas Eggert | — | — | 2018-09 |
| Clare Kahn | — | — | 2018-09 |
| Isaac T. Blech | — | — | 2018-09 |
| Richard Kenney | — | — | 2018-09 |
| Robert R. Ruffolo | — | — | 2018-09 |
| Ulf Wiinberg | — | — | 2018-09 |
X-Vax Technology, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Alveo Technologies Inc. | Biotechnology | Series C | $63.6M | $503.5M | network1 shared operator · same sector · same stage |
| Istari Oncology, Inc. | Biotechnology | Series C | $48.6M | $1.4B | network1 shared operator · same sector · same stage |
| Sapience Therapeutics, Inc. | Biotechnology | Series B | $30.8M | $317.9M | network2 shared operators · same sector |
| Elicio Therapeutics, Inc. | Biotechnology | Series B | $105.3M | $392.9M | network2 shared operators · same sector |
| Elucida Oncology, Inc. | Biotechnology | Series B | $117.1M | $255.6M | network2 shared operators · same sector |
| Viracta Therapeutics, INC. | Biotechnology | Series C | $164.6M | $2.1B | network1 shared operator · same sector · same stage |
| Centrexion Therapeutics Corp | Biotechnology | Series C | $202.0M | $35.3M | network1 shared operator · same sector · same stage |
| Angion Biomedica Corp. | Biotechnology | Series B | $52.0M | $48.4M | network1 shared operator · same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| X-Biomedical Inc. | Biotechnology | Pre-Seed | $23.5M | 93% |
| Xeno Biosciences Inc. | Biotechnology | Series A | $16.4M | 91% |
| Vaxess Technologies, Inc. | Biotechnology | Series C | $270.2M | 90% |
| Xenetic Biosciences, Inc. | Biotechnology | Series A | $5.9M | 90% |
| CancerVAX, Inc. | Biotechnology | Pre-Seed | $7.2M | 90% |
| X-Rase RD Development, LLC | Biotechnology | Seed | $41.4M | 89% |
| Xcell Biosciences, Inc. | Biotechnology | Series B | $8.3M | 89% |
| XenoTherapeutics Corp | Biotechnology | Seed | $39.0M | 88% |
See where X-Vax Technology, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at X-Vax Technology, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.